Phase I and pharmacologic study of the combination of paclitaxel, cisplatin and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer

V.M.M. Herben, J.H.M. Schellens, J.H. Beijnen

Research output: Contribution to journalArticleProfessional

Original languageUndefined/Unknown
Pages (from-to)747-755
Number of pages8
JournalJournal of Clinical Oncology
Volume17
Publication statusPublished - 1999

Cite this